| Name | Title | Contact Details |
|---|---|---|
Chris Moore |
General Counsel | Profile |
Mustang Bio, Inc., a subsidiary of Fortress Biotech, Inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient`s own immune system to eliminate cancer cells. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. Mustang has partnered with the City of Hope National Medical Center (“COH”) and Fred Hutchinson Cancer Research Center in the development of proprietary chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies across many cancers. Mustang`s lead programs are in Phase 1 clinical trials at COH: MB-101 for the treatment of brain cancer and MB-102 as a therapeutic agent in acute myeloid leukemia.
Shiel offers a comprehensive menu of test and diagnostic options through participating physicians and health care providers, and through our ever expanding Patient Service Center Network. Our full-service in-house pathology department performs GYN (Pap
606018 F. Hoffmann-La Roche AG is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics.
Onco360 provides industry-leading Oncology Pharmacy services for Patients, Physicians, Pharma, Payers, & Hospitals. Learn more.
Were reimagining how technology can solve #stroke`s unmet needs, enabling providers with the ability to raise the standard of care for patients.